Etrasimoddosage

Assessments are required prior to initiating VELSIPITY.

The recommended dosage is 2 mg orally once daily.

2.1 Assessments,

Medications, and Vaccinations Prior to First Dose of VELSIPITY Before initiation of treatment with VELSIPITY, assess the following: Complete Blood Count Obtain a recent (i.e., within the last 6 months or after discontinuation of prior UC therapy) complete blood count (CBC), including lymphocyte count. Cardiac Evaluation Obtain an electrocardiogram (ECG) to determine whether preexisting conduction abnormalities are present. In patients with certain preexisting conditions, advice from a cardiologist should be sought. Liver Function Tests Obtain recent (i.e., within the last 6 months) transaminase and bilirubin levels. Ophthalmic Assessment Obtain a baseline evaluation of the fundus, including the macula, near the start of treatment with VELSIPITY. Skin Examination Obtain a skin examination prior to or shortly after initiation of VELSIPITY. If a suspicious skin lesion is observed, it should be promptly evaluated. Current or Prior Medications

Determine if patients are taking drugs that could slow heart rate or atrioventricular (AV) conduction.

If patients are taking anti-neoplastic, immune-modulating, or non-corticosteroid immunosuppressive therapies, or if there is a history of prior use of these drugs, consider possible unintended additive immunosuppressive effects before initiating treatment with VELSIPITY. Vaccinations Patients without a healthcare professional-confirmed history of varicella (chickenpox) or without documentation of a full course of vaccination against varicella zoster virus (VZV) should be tested for antibodies to VZV before initiating VELSIPITY; VZV vaccination of antibody-negative patients is recommended prior to commencing treatment with VELSIPITY. If live attenuated vaccine immunizations are required, administer at least 4 weeks prior to initiation of VELSIPITY. Update immunizations in agreement with current immunization guidelines prior to initiating VELSIPITY therapy.

2.2 Recommended

Dosage

The recommended dosage of VELSIPITY is 2 mg orally once daily.

Swallow the tablet whole, with or without food.

If a dose is missed, take the missed dose at the next scheduled time; do not double the next dose.